Ambuja Cements Q3 preview: Ambuja Cements (ACL), an Adani Group company, is projected to report mixed Q3FY25 performance, with revenues estimated at ₹8,022–₹9,076 crore. PAT could decline 6.2%-32% YoY, while volumes are expected to rise.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected